{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T04:53:56Z","timestamp":1776315236298,"version":"3.50.1"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:00:00Z","timestamp":1776297600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:00:00Z","timestamp":1776297600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CVIR Endovasc"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To evaluate the impact of fibrinogen monitoring on bleeding complications and rates of premature tPA cessation in patients undergoing catheter-directed thrombolysis (CDT). We hypothesize that routine fibrinogen monitoring does not lower bleeding complications but may result in more cases of incomplete thrombolysis due to premature tPA termination.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This single-institution retrospective study examined patients who underwent CDT for arterial, venous, or pulmonary thrombosis from 2011 to 2023. Rates of significant hemorrhages and premature tPA cessation were compared in patients with and without routine fibrinogen monitoring. Premature tPA cessation was defined as termination of thrombolytic infusion prior to the planned treatment endpoint due to low fibrinogen levels or clinical bleeding concerns.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 355 CDT procedures met inclusion criteria, including 225 cases without routine monitoring (control group) and 130 with routine fibrinogen monitoring. Bleeding rates were similar between groups (3.55% vs. 3.07%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20091.00). However, premature tPA cessation occurred significantly more frequently in the fibrinogen monitoring cohort (17.5% vs. 1.78%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Among cases with premature tPA cessation, residual thrombus requiring adjunctive interventions was common.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study demonstrated that routine fibrinogen monitoring was not associated with significantly reduced bleeding complications, but is linked to higher rates of premature tPA cessation in stable patients, which may contribute to incomplete thrombolysis and increased need for adjunctive interventions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical Abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1186\/s42155-026-00682-y","type":"journal-article","created":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T04:20:29Z","timestamp":1776313229000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Fibrinogen monitoring does not significantly reduce rates of bleeding complications during catheter-directed thrombolysis"],"prefix":"10.1186","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-4275-7632","authenticated-orcid":false,"given":"Minh A.","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire S.","family":"Kaufman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,16]]},"reference":[{"issue":"5","key":"682_CR1","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.avsg.2009.12.011","volume":"24","author":"SC Agle","year":"2010","unstructured":"Agle SC, McNally MM, Powell CS, Bogey WM, Parker FM, Stoner MC. The association of periprocedural hypertension and adverse outcomes in patients undergoing catheter-directed thrombolysis. Ann Vasc Surg. 2010;24(5):609\u201314. https:\/\/doi.org\/10.1016\/j.avsg.2009.12.011.","journal-title":"Ann Vasc Surg"},{"issue":"4","key":"682_CR2","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.jvir.2019.12.003","volume":"31","author":"A Graif","year":"2020","unstructured":"Graif A, Kimbiris G, Grilli CJ, Agriantonis DJ, Putnam SG, Leung DA. Safety of therapeutic anticoagulation with low-molecular-weight heparin or unfractionated heparin infusion during catheter-directed thrombolysis for acute pulmonary embolism. J Vasc Interv Radiol. 2020;31(4):537\u201343. https:\/\/doi.org\/10.1016\/j.jvir.2019.12.003.","journal-title":"J Vasc Interv Radiol"},{"issue":"23","key":"682_CR3","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1056\/NEJMoa1615066","volume":"377","author":"S Vedantham","year":"2017","unstructured":"Vedantham S, Goldhaber SZ, Julian JA, Kahn SR, Jaff MR, Cohen DJ, et al. Pharmacomechanical catheter-directed thrombolysis for deep-vein thrombosis. N Engl J Med. 2017;377(23):2240\u201352. https:\/\/doi.org\/10.1056\/NEJMoa1615066.","journal-title":"N Engl J Med"},{"issue":"11","key":"682_CR4","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000985.pub3","volume":"11","author":"C Broderick","year":"2021","unstructured":"Broderick C, Patel JV. Infusion techniques for peripheral arterial thrombolysis. Cochrane Database Syst Rev. 2021;11(11):CD000985. https:\/\/doi.org\/10.1002\/14651858.CD000985.pub3.","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"682_CR5","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/s1051-0443(07)61420-1","volume":"11","author":"K Ouriel","year":"2000","unstructured":"Ouriel K, Gray B, Clair DG, Olin J. Complications associated with the use of urokinase and recombinant tissue plasminogen activator for catheter-directed peripheral arterial and venous thrombolysis. J Vasc Interv Radiol. 2000;11(3):295\u20138. https:\/\/doi.org\/10.1016\/s1051-0443(07)61420-1.","journal-title":"J Vasc Interv Radiol"},{"issue":"2","key":"682_CR6","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.jvs.2010.01.080","volume":"52","author":"JC van den Berg","year":"2010","unstructured":"van den Berg JC. Thrombolysis for acute arterial occlusion. J Vasc Surg. 2010;52(2):512\u20135. https:\/\/doi.org\/10.1016\/j.jvs.2010.01.080.","journal-title":"J Vasc Surg"},{"issue":"8","key":"682_CR7","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1016\/j.jvir.2020.04.032","volume":"31","author":"A Graif","year":"2020","unstructured":"Graif A, Grilli CJ, Kimbiris G, Paik HH, Leung DA. Evaluation of fibrinogen levels during catheter-directed thrombolysis for acute pulmonary embolism. J Vasc Interv Radiol. 2020;31(8):1281\u20139. https:\/\/doi.org\/10.1016\/j.jvir.2020.04.032.","journal-title":"J Vasc Interv Radiol"},{"issue":"7","key":"682_CR8","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1177\/1538574415611234","volume":"49","author":"K Lee","year":"2015","unstructured":"Lee K, Istl A, Dubois L, DeRose G, Forbes TL, Wiseman D, et al. Fibrinogen level and bleeding risk during catheter-directed thrombolysis using tissue plasminogen activator. Vasc Endovasc Surg. 2015;49(7):175\u20139. https:\/\/doi.org\/10.1177\/1538574415611234.","journal-title":"Vasc Endovasc Surg"},{"issue":"7","key":"682_CR9","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1177\/1538574413497107","volume":"47","author":"N Skeik","year":"2013","unstructured":"Skeik N, Gits CC, Ehrenwald E, Cragg AH. Fibrinogen level as a surrogate for the outcome of thrombolytic therapy using tissue plasminogen activator for acute lower extremity intravascular thrombosis. Vasc Endovasc Surg. 2013;47(7):519\u201323. https:\/\/doi.org\/10.1177\/1538574413497107.","journal-title":"Vasc Endovasc Surg"},{"issue":"3\u20134","key":"682_CR10","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1053\/j.semvascsurg.2015.04.003","volume":"27","author":"RL Ross","year":"2014","unstructured":"Ross RL, Beck AW. Fibrinogen and catheter-directed thrombolysis. Semin Vasc Surg. 2014;27(3\u20134):182\u201395. https:\/\/doi.org\/10.1053\/j.semvascsurg.2015.04.003.","journal-title":"Semin Vasc Surg"},{"issue":"8","key":"682_CR11","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1016\/j.jvir.2020.05.014","volume":"31","author":"AK Sista","year":"2020","unstructured":"Sista AK. Fibrinogen monitoring during catheter-directed thrombolysis for pulmonary embolism: can it be cleaved from our practice? J Vasc Interv Radiol. 2020;31(8):1290\u20131. https:\/\/doi.org\/10.1016\/j.jvir.2020.05.014.","journal-title":"J Vasc Interv Radiol"},{"issue":"5","key":"682_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/jcm7050111","volume":"7","author":"C Kaufman","year":"2018","unstructured":"Kaufman C, Kinney T, Quencer K. Practice trends of fibrinogen monitoring in thrombolysis. J Clin Med. 2018;7(5):111. https:\/\/doi.org\/10.3390\/jcm7050111.","journal-title":"J Clin Med"},{"issue":"5","key":"682_CR13","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1016\/j.jvs.2016.11.025","volume":"65","author":"MHF Poorthuis","year":"2017","unstructured":"Poorthuis MHF, Brand EC, Hazenberg CEVB, Schutgens REG, Westerink J, Moll FL, et al. Plasma fibrinogen level as a potential predictor of hemorrhagic complications after catheter-directed thrombolysis for peripheral arterial occlusions. J Vasc Surg. 2017;65(5):1519-1527.e26. https:\/\/doi.org\/10.1016\/j.jvs.2016.11.025.","journal-title":"J Vasc Surg"},{"key":"682_CR14","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.avsg.2023.08.020","volume":"99","author":"T Dorey","year":"2024","unstructured":"Dorey T, Kong D, Lobo W, Hanlon E, Abramowitz S, Turcotte J, et al. Plasma fibrinogen change as a predictor of major bleeding during catheter-directed thrombolysis. Ann Vasc Surg. 2024;99:262\u201371. https:\/\/doi.org\/10.1016\/j.avsg.2023.08.020.","journal-title":"Ann Vasc Surg"},{"key":"682_CR15","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000985.pub2","volume":"1","author":"DO Kessel","year":"2004","unstructured":"Kessel DO, Berridge DC, Robertson I. Infusion techniques for peripheral arterial thrombolysis. Cochrane Database Syst Rev. 2004;1:CD000985. https:\/\/doi.org\/10.1002\/14651858.CD000985.pub2.","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"682_CR16","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1111\/j.1538-7836.2012.04728.x","volume":"10","author":"VJ Marder","year":"2012","unstructured":"Marder VJ, Comerota AJ, Shlansky-Goldberg RD, Davis JP, Deng C, Hanna K, et al. Safety of catheter-delivered plasmin in patients with acute lower extremity arterial or bypass graft occlusion: phase i results. Journal of thrombosis and haemostasis\u202f: JTH. 2012;10(6):985\u201391. https:\/\/doi.org\/10.1111\/j.1538-7836.2012.04728.x.","journal-title":"Journal of thrombosis and haemostasis : JTH"}],"container-title":["CVIR Endovascular"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42155-026-00682-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s42155-026-00682-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42155-026-00682-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T04:20:30Z","timestamp":1776313230000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s42155-026-00682-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,16]]},"references-count":16,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["682"],"URL":"https:\/\/doi.org\/10.1186\/s42155-026-00682-y","relation":{},"ISSN":["2520-8934"],"issn-type":[{"value":"2520-8934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,16]]},"assertion":[{"value":"10 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the OHSU Institutional Review Board (IRB).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"40"}}